Dr Reddy’s Laboratories trades in green on the BSE

Dr Reddys Laboratories is currently trading at Rs. 3495.30, up by 64.40 points or 1.88% from its previous closing of Rs. 3430.90 on the BSE. The scrip opened at Rs. 3454.00 and has touched a high and low of Rs. 3511.00 and Rs. 3431.30 respectively. So far 16903 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3503.55 on 13-Nov-2014 and a 52 week low of Rs. 2250.00 on 19-May-2014. Last one week high and low of the scrip stood at Rs. 3503.55 and Rs. 3370.00 respectively. The current market cap of the company is Rs. 59394.64 crore. The promoters holding in the company stood at 25.49 % while Institutions and Non-Institutions held 43.79 % and 13.69 % respectively. Dr Reddy’s Laboratories and US firm Endo International Plc have received final approval from US Food and Drug Administration (US FDA) to make cheaper copies of Roche Holding AG's antiviral Valcyte. The move comes after Ranbaxy Laboratories on Thursday said that FDA had stripped the company of its tentative approval to launch the first copy of the drug due to quality control issues at its manufacturing plants. Ranbaxy, whose all India-based manufacturing plants have been banned by the FDA from exporting to the United States, also lost its rights to a six-month market exclusivity for Valcyte generic. Dr. Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.